China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase a substantial 28% stake in fellow Chinese firm Tasly Pharmaceuticals (SHA: 600535). The transaction involves the acquisition of 418,306,002 shares, with a proposed consideration of RMB 14.85 per share, culminating in a total deal value of RMB 6.21 billion (approximately USD 870 million).
This strategic acquisition is poised to strengthen CR Sanjiu’s dominant position within the pharmaceutical industry and is expected to enhance its core competitiveness. The deal underscores CR Sanjiu’s commitment to expanding its market influence and underscores its ambition to become a key player in the global healthcare sector.- Flcube.com
